drugset
drugset / Trial / NCT04161118

TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma

NCT04161118 ↗

Phase 2 Terminated 3 enrolled University of Cologne Novartis · collab
NaSingle-groupOpen-labelTreatment

Summary

A phase II trial of TisaGenlecleucel (CTL019) in Elderly Patients with First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Timeline

Start
2021-05-12
Primary completion
2023-02-24
Completion
2023-02-24

Outcome

Outcome not reported

Stopped (Enrollment): “Termination of the funding agreement by the financial sponsor of the study. Small number of patients enrolled, none of the planned analyses will be feasible to draw conclusions on the safety or efficacy of the therapy.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Tisagenlecleucel Cell therapy 6e+07 cells Intravenous
Subject Tisagenlecleucel Cell therapy 6e+08 cells Intravenous

Indications

non-Hodgkin lymphoma